The time is now: John Cox assumes CEO post at Flagship-backed Torque, steering cell therapy to clinical trials
A stealthy Torque Therapeutics is in the midst of raising a Series B round to bankroll an upcoming slate of clinical studies for its cancer cell therapy platform — and it will all be overseen by a new CEO.
John Cox, executive chairman since January, is taking over from Bart Henderson as the former chief pursues some other work with Flagship Pioneering.
The appointment marks the first full-time gig for Cox since he flipped Biogen’s hemophilia-focused spinout Bioverativ to Sanofi for $11.6 billion, earning a payout worth more than $85 million in the process. The little taste he had of cell therapy there, albeit for a distinctly different application, helped convince him that it’s a modality for the future. He envisions Torque becoming the definitive immuno-oncology cell therapy company, and the time is now to jump in.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.